Share price and RNS

To view the latest share price data and regulatory news service announcements for Sareum plc please click on the links below.

Sareum Holdings News and Articles from

Proactive Investors logo

RNS press release - FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2018
1st October 2018
RNS press release - Notice of Results
27th September 2018
News - Sareum selects potential anti-cancer molecule for further development
26th September 2018
Sareum Holdings Plc (LON:SAR) has selected another candidate molecule from its TYK2 inhibitor programme to take through the clinic, this time as a potential therapy for certain cancers. Earlier this month, the AIM company went with SDC-1801 as a &l…
RNS press release - TYK2/JAK1 selected for certain cancers
26th September 2018
News - Sareum reports “strong progress” made with in-house and out-licensed drug programmes
11th September 2018
Sareum Holdings Plc (LON:SAR) has highlighted the progress made by its in-house and out-licensed drug programmes over the past year. US firm Sierra Oncology, which is the licence holder of Sareum’s SRA737 checkpoint kinase 1 (Chk1) inhibitor …
50

  • @Sareumplc Latest tweet

    Roche's discontinuation of its CHK1 inhibitor, RG7741 (aka Genentech's GDC-0575), means this mechanism is now a two… https://t.co/xq9zzVT44p via @Sareumplc
    View more

Contact

Sareum Limited
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge CB22 3FX
United Kingdom


tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
email_white.png

Downloads

Full Year Results 2018 (0.8 MB)

Annual report PDF 2017 (2.3MB)

  Annual Report 2017